JP2022536581A5 - - Google Patents

Info

Publication number
JP2022536581A5
JP2022536581A5 JP2021561910A JP2021561910A JP2022536581A5 JP 2022536581 A5 JP2022536581 A5 JP 2022536581A5 JP 2021561910 A JP2021561910 A JP 2021561910A JP 2021561910 A JP2021561910 A JP 2021561910A JP 2022536581 A5 JP2022536581 A5 JP 2022536581A5
Authority
JP
Japan
Application number
JP2021561910A
Other languages
Japanese (ja)
Other versions
JPWO2020257191A5 (https=
JP2022536581A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037919 external-priority patent/WO2020257191A1/en
Publication of JP2022536581A publication Critical patent/JP2022536581A/ja
Publication of JPWO2020257191A5 publication Critical patent/JPWO2020257191A5/ja
Publication of JP2022536581A5 publication Critical patent/JP2022536581A5/ja
Pending legal-status Critical Current

Links

JP2021561910A 2019-06-19 2020-06-16 多量体t細胞調節性ポリペプチド及びその使用方法 Pending JP2022536581A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863754P 2019-06-19 2019-06-19
US62/863,754 2019-06-19
PCT/US2020/037919 WO2020257191A1 (en) 2019-06-19 2020-06-16 Multimeric t-cell modulatory polypeptides and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022536581A JP2022536581A (ja) 2022-08-18
JPWO2020257191A5 JPWO2020257191A5 (https=) 2023-06-16
JP2022536581A5 true JP2022536581A5 (https=) 2023-06-16

Family

ID=74040105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021561910A Pending JP2022536581A (ja) 2019-06-19 2020-06-16 多量体t細胞調節性ポリペプチド及びその使用方法

Country Status (4)

Country Link
US (1) US20220017597A1 (https=)
EP (1) EP3986448A4 (https=)
JP (1) JP2022536581A (https=)
WO (1) WO2020257191A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3019005A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN116970059A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
AU2019401183A1 (en) * 2018-12-19 2021-08-12 Cue Biopharma, Inc. Multimeric T-cell modulatory polypeptides and methods of use thereof
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體t細胞調節多肽及其使用方法
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
US20240092899A1 (en) * 2021-02-07 2024-03-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bispecific antibody
JP2024512470A (ja) * 2021-03-19 2024-03-19 キュー バイオファーマ, インコーポレイテッド T細胞調節ポリペプチド及びその使用方法
JP2024518680A (ja) * 2021-03-19 2024-05-02 キュー バイオファーマ, インコーポレイテッド T細胞調節ポリペプチド及びその使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2357960T3 (es) * 1997-05-08 2011-05-04 Oncothyreon Inc. Procedimiento para generar células t activadas y células presentadoras de antígenos pulsadas con antígenos.
US7696306B2 (en) * 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
BR112015002091A2 (pt) * 2012-08-02 2017-12-12 Hoffmann La Roche método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
PL3157552T3 (pl) * 2014-06-18 2020-05-18 Albert Einstein College Of Medicine Polipeptydy syntac i ich zastosowania
EP3328377A4 (en) * 2015-07-31 2019-03-13 Tarveda Therapeutics, Inc. COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY THERAPIES
AU2017225787B2 (en) * 2016-03-03 2021-09-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2017226199A1 (en) * 2016-03-04 2018-09-13 New York University Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
CA3019005A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
BR122020025384B1 (pt) * 2016-12-13 2022-07-12 Delinia, Inc Proteínas de fusão e dimérica, usos das mesmas e composição farmacêutica
CN116970059A (zh) * 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
JP2020510038A (ja) * 2017-03-09 2020-04-02 プレジデント アンド フェローズ オブ ハーバード カレッジ がんワクチン
IL269000B2 (en) * 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
EP3446702A1 (en) * 2017-08-23 2019-02-27 Medizinische Hochschule Hannover Synthetic vaccine
TW201920249A (zh) * 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
EP3678691A4 (en) * 2017-09-07 2021-06-09 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)